INTRODUCTION
============

Cytomegalovirus (CMV) infection is a representative opportunistic infection that can affect graft and patient survival in kidney transplant recipients (KTRs) \[[@b1-kjim-2017-040]\]. Indeed, CMV infection can result in CMV disease or syndrome affecting various organs, but it can also cause opportunistic infection, acute rejection or even further secondary malignancy by dysregulation of the immune status of recipients \[[@b2-kjim-2017-040]\]. Therefore, effective prophylaxis or early treatment for CMV infection after kidney transplantation (KT) is very important to improve allograft outcomes.

To date, various factors have been reported to be associated with the development of CMV infection, but many studies showed that the use of anti-thymocyte globulin (ATG) is one of the most important risk factors \[[@b3-kjim-2017-040]\]. ATG is a strong lymphocyte depleting agent, and it is used as induction therapy for immunologically high risk KTRs or a secondary treatment option for steroid-resistant acute T-cell mediated rejection (TCMR). However, weakened lymphocyte activity by ATG can cause vulnerability to CMV infection in KTRs, which justifies the use of CMV prophylaxis after ATG treatment \[[@b4-kjim-2017-040]\].

Usually, intravenous ganciclovir is used during ATG treatment for CMV prophylaxis \[[@b5-kjim-2017-040]\]. In addition, maintenance oral ganciclovir or valganciclovir is recommended during 1 to 3 months after the completion of ATG treatment; however, the use of maintenance therapy is limited in many cases because of the high cost \[[@b6-kjim-2017-040]\]. A recent report showed that valacyclovir is not only cost effective but it also has a similar efficacy in prevention of CMV infection in comparison with oral ganciclovir or valganciclovir in KTRs who received ATG induction therapy \[[@b7-kjim-2017-040],[@b8-kjim-2017-040]\]. However, the usefulness of valacyclovir in the prevention of CMV infection in KTRs who received ATG as anti-rejection therapy has not been reported.

In this regard, the aim of this study is to evaluate the effect of maintenance valacyclovir universal prophylaxis against CMV infection after intravenous ganciclovir during ATG treatment as anti-rejection therapy for steroid resistant TCMR.

METHODS
=======

Study population
----------------

We included a total of 55 adult KT recipients who received ATG for the treatment of steroid resistant rejection in Seoul St. Mary's Hospital between January 2010 and April 2016. TCMR was diagnosed based on Banff classification \[[@b9-kjim-2017-040]\]. According to the anti-rejection treatment protocol of Seoul St. Mary's Hospital, TCMR was treated with 3 to 5 daily boluses of intravenous methylprednisolone (500 mg/day), followed by a 5 to 7 day oral steroid taper. However, when the serum creatinine level failed to decrease within 5 days, we regarded it as steroid resistant rejection and ATG was applied \[[@b10-kjim-2017-040]\]. All recipients received ATG injection (1.5 mg/kg/day) for a week.

CMV prophylaxis protocol in KTRs who received ATG as anti-rejection therapy was as follows ([Fig. 1](#f1-kjim-2017-040){ref-type="fig"}): In all 55 KTRs, we used intravenous ganciclovir during ATG injection at a dose of 2.5 mg/kg twice a day, and the dose was modified according to the allograft function of each patient \[[@b11-kjim-2017-040],[@b12-kjim-2017-040]\]. After the completion of ATG therapy, plasma CMV DNA real-time polymerase chain reaction (PCR) was checked on D7, 1, 3, 6, 9, and 12 months, and when the CMV copy number exceeded 2,000 copies/mL, we used intravenous ganciclovir therapy.

Before July 2013, we used preemptive therapy for CMV infection; in brief, the recipients received intravenous ganciclovir therapy only when CMV infection was detected without the use of anti-viral agent prophylaxis. These 34 KTRs belonged to the historic control group (CONT, n = 34). After July 2013, we used maintenance valacyclovir at a dosage of 2 g four times daily by mouth during 1 month after the completion of ATG therapy, in addition to the previous prophylaxis protocol \[[@b8-kjim-2017-040]\]. Twenty-one patients who received this revised protocol belonged to the valacyclovir study group (VAL, n = 21). We compared the clinical outcomes and parameters between the CONT and VAL groups. This retrospective study was approved by the Institutional Review Board of our institution (KC140NMI0460), which waived the requirement for informed consent.

Clinical and biochemical data
-----------------------------

We collected the baseline characteristics of the recipients, including sex and age. Data about transplantation included the number of human leukocyte antigen mismatches, pretransplant panel reactive antibody, positivity of cross match study, pretransplant CMV serostatus, and posttransplant immunosuppressant regimen. Clinical information, such as pathologic findings of rejection, time interval from transplantation to ATG treatment, duration of ATG administration, total dose of ATG, and duration of valacyclovir administration, was assessed.

Efficacy of valacyclovir prophylaxis for CMV infection
------------------------------------------------------

The primary outcome of this study was the incidence of CMV infection after ATG treatment for steroid resistant TCMR. CMV infection was defined as CMV viremia (≥ 500 copies/mL) using quantitative CMV PCR, irrespective of the symptoms. The secondary outcomes of this study were CMV disease, subsequent acute rejection, graft function assessed as estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration formula, adverse events, death-censored allograft survival, and patient survival rate \[[@b13-kjim-2017-040]\]. CMV disease was defined as symptomatic infection. Clinical symptoms included CMV syndrome (fever, and one or more of the following findings: constitutional symptoms, leukopenia, thrombocytopenia, or liver enzyme elevation) or tissue-invasive CMV disease \[[@b14-kjim-2017-040]\].

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 23.0 (IBM Co., Armonk, NY, USA). Data are presented as mean ± standard deviation or counts and percentages, depending on the data type. For continuous variables, means were compared using Student *t* test. For categorized variables, Pearson chi-square test and Fisher exact test were used. Patient, graft and CMV-free survival rates were calculated using Kaplan-Meier analysis, and we used the log-rank method to compare the survival rates between the VAL and CONT groups. All tests were two-tailed, and the results were considered statistically significant when the *p* value was less than 0.05.

RESULTS
=======

Comparison of baseline characteristics
--------------------------------------

The comparison of baseline characteristics between the VAL group and the CONT group is presented in [Table 1](#t1-kjim-2017-040){ref-type="table"}. Demographic characteristics such as patient's mean age at the time of TCMR diagnosis and sex ratio were not different between the two groups. The pretransplant immunologic status and CMV serostatus of donors and recipients, and the time interval from KT to ATG administration did not differ significantly between the two groups (*p* \> 0.05, respectively) ([Table 1](#t1-kjim-2017-040){ref-type="table"}). At the time of allograft biopsy, immune suppression regimens, pathologic findings at biopsy, allograft function and the duration or administered amount of ATG also showed no differences. The allograft function at biopsy also did not differ between the two groups. The mean duration of valacyclovir administration was 28.3 ± 5 days in the VAL group.

Comparison of the development of CMV infection
----------------------------------------------

The incidence of CMV infection was significantly lower in the VAL group (2/21, 9.6%) compared to the CONT group (23/34, 67.6%; *p* \< 0.001) ([Fig. 2A](#f2-kjim-2017-040){ref-type="fig"}). With respect to the interval between ATG administration and CMV infection, it was significantly shorter in the CONT group (34.8 ± 19 days) than in the VAL group (101 ± 33 days, *p* \< 0.001 vs. CONT group). In the CONT group, all CMV infections occurred within the first 3 months after ATG treatment. On the other hand, in the VAL group, all cases of CMV infection occurred after 1 month. Therefore, the 1-year CMV-free survival rate was significantly higher in the VAL group compared to the control group (80% vs. 38.6%, *p* = 0.009) ([Fig. 2B](#f2-kjim-2017-040){ref-type="fig"}). In the VAL group, all cases of CMV infection were limited to CMV viremia. In contrast, in the CONT group, three cases of CMV disease were detected; one case of CMV nephritis, proven by kidney biopsy, and two cases of CMV syndrome.

Comparison of adverse events associated with anti-viral treatment
-----------------------------------------------------------------

The cumulative incidence of leukopenia (\< 4.0 × 10^9^/L) (CONT, 32% \[11/34\] vs. VAL, 23% \[5/21\]; *p* = 0.556), anemia (hemoglobin \< 9 g/dL) (CONT, 24% \[8/34\] vs. VAL, 33% \[7/21\]; *p* = 0.272), and thrombocytopenia (\< 100 × 10^9^/L) (CONT, 9% \[3/34\] vs. VAL, 14% \[3/21\]; *p* = 0.664), did not differ between the CONT and VAL groups ([Table 2](#t2-kjim-2017-040){ref-type="table"}). This indicates that valacyclovir did not increase the risk of bone marrow suppression, and it had no additional effect. In six patients, valacyclovir was withheld within 1 month because of deterioration of allograft function. However, there were no clinically important side effects associated with valacyclovir such as hallucination and/or confusion.

Comparison of allograft outcomes after CMV infection
----------------------------------------------------

There was no significant difference in subsequent acute rejection after ATG treatment between the two groups ([Fig. 3A](#f3-kjim-2017-040){ref-type="fig"}). The incidence of subsequent acute rejection after ATG treatment was 41.1% (14/34) in the CONT group, whereas the incidence of subsequent acute rejection after ATG treatment was 33.3% (7/21) in the VAL group (*p* = 0.776). The allograft survival rate after allograft rejection also did not differ between the two groups (*p* = 0.508) ([Fig. 3B](#f3-kjim-2017-040){ref-type="fig"}). In the CONT group, graft failure occurred in 70.5% of the cases (24/34), while in the VAL group, graft failure occurred in 47.6% of the cases (10/21) (*p* = 0.152). Chronic rejection was the main cause of graft failure in both groups (CONT, 87.5% \[21/24\] vs. VAL, 100% \[10/10\]; *p* = 0.067). Allograft function showed a lower tendency in the CONT group after ATG treatment; however, the differences were not significant ([Fig. 3C](#f3-kjim-2017-040){ref-type="fig"}). There was no patient death in the VAL group, and there were two cases of death in the CONT group. In the CONT group, one patient died of urothelial cancer of the kidney and the other patient died of atypical pneumonia. Patient survival rate showed no difference between the two groups (*p* = 0.480).

DISCUSSION
==========

In this study, we investigated the usefulness of valacyclovir prophylaxis against CMV infection after ATG treatment for steroid resistant TCMR. We found that the incidence of CMV infection after ATG therapy was significantly lower in the VAL group in comparison with the CONT group with similar other clinical outcomes. This suggests that valacyclovir can be recommended as a first-line prophylactic agent for patients who received ATG as anti-rejection therapy.

First, we focused on the high risk of CMV infection after ATG treatment as induction therapy or anti-rejection therapy \[[@b4-kjim-2017-040],[@b15-kjim-2017-040]\]. In KTRs who received ATG as induction therapy, the incidence of CMV infection was reported to be 67%, and in KTRs who received ATG therapy, it was reported to be 33%, which was significantly higher than in KTRs who received only steroid pulse therapy \[[@b2-kjim-2017-040],[@b16-kjim-2017-040]\]. In this study, the incidence of CMV infection in the CONT group was nearly 67.6% in spite of the use of intravenous ganciclovir during ATG treatment. This strongly suggests that maintenance therapy with an anti-viral agent after the end of ATG therapy is required, and therefore, we changed our center's CMV prophylaxis protocol in KTRs who received ATG therapy as anti-rejection therapy after July 2013 \[[@b17-kjim-2017-040]\].

Our next concern was the choice of anti-viral agents. In case of ATG induction therapy, oral ganciclovir or valganciclovir is commonly recommended \[[@b17-kjim-2017-040]\]. In addition, oral valacyclovir showed similar efficacy in the prevention of CMV infection in well-designed clinical trials \[[@b7-kjim-2017-040],[@b8-kjim-2017-040]\]. Cost-effectiveness of valacyclovir in comparison with oral ganciclovir or valganciclovir further justified the use of this drug in these patients. Acyclovir also showed anti-CMV activity with similar cost-effectiveness as valacyclovir. However, the effectiveness and bioavailability of oral acyclovir are significantly lower than that of valacyclovir \[[@b18-kjim-2017-040]\]. Therefore, we thought that valacyclovir could be a promising option instead of oral ganciclovir or valganciclovir, as it showed similar effectiveness and better cost-effectiveness.

Indeed, use of valacyclovir prophylaxis significantly lowered the incidence of CMV infection, and further, the infection itself was less severe in the VAL group in comparison with the CONT group in this study. There were only two episodes of CMV infections in the VAL group, which were limited to CMV viremia, the mild form of infection, and there was no clinical symptomatic CMV disease. However, there were several cases of CMV syndrome and biopsy-proven CMV nephritis in the CONT group. In addition, valacyclovir reduced the incidence of CMV infection immediately after ATG treatment, during which leukopenia is common due to ATG therapy, as shown in this study. CMV infection during this period can result in more a severe immunocompromised state, which can be associated with other secondary opportunistic infections \[[@b19-kjim-2017-040]-[@b22-kjim-2017-040]\]. This finding suggests that valacyclovir prophylaxis may prevent critical CMV infection, which may result in patient morbidity or mortality.

The final issue is the adverse effect due to maintenance anti-viral therapy. The previous study has shown that antiviral agents for CMV prophylaxis can have an adverse effect such as bone marrow suppression (anemia, leukopenia, and thrombocytopenia) or psychiatric side effect such as hallucination or confusion, which may limit the use of these maintenance drugs \[[@b2-kjim-2017-040],[@b7-kjim-2017-040],[@b23-kjim-2017-040]\]. But in this study, there was no difference in bone marrow suppression events between the two groups, which suggests that these side effects are not associated with valacyclovir but with the effect of ATG administration \[[@b20-kjim-2017-040]-[@b22-kjim-2017-040],[@b24-kjim-2017-040]-[@b26-kjim-2017-040]\]. In addition, there were no typical psychiatric adverse events in the VAL group. All these results suggest that proper dose modification with close monitoring can minimize the adverse effects of valacyclovir. In this study, the main reason for requiring dose reduction or discontinuation was deterioration of allograft function, and it may be because of the progression of acute rejection and not because of the use of valacyclovir.

There are some limitations to this study. At first, this was a retrospective study with a limited sample size and a single-center design. Since it was retrospective study, patient's adherence to valacyclovir could not be assessed. Also, we compared the historic control group (previous protocol) with the study group (revised protocol), which might cause selection bias. Second, we did not compare the effect of valacyclovir with that of oral ganciclovir or valganciclovir, which is generally recommended for CMV prophylaxis. Further prospective randomized-controlled trial with a large sample size is needed.

In conclusion, given the increasing incidence of post-ATG CMV disease, valacyclovir could be the appropriate drug for prophylaxis for CMV disease without any concern about significant side effects after ATG treatment for steroid resistant TCMR.

KEY MESSAGE
===========

1\. Cytomegalovirus (CMV) infection affects the graft and patient survival in kidney transplant recipients.

2\. Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection can increase the risk of CMV infection.

3\. Valacyclovir prophylaxis prevents CMV infection after ATG treatment without any concern about significant side effects.
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![Cytomegalovirus (CMV) prophylaxis protocol in kidney transplant recipients (KTRs) who received anti-thymocyte globulin (ATG) as anti-rejection therapy. All KTRs were given intravenous ganciclovir (GCV) during ATG treatment (2.5 mg/kg twice a day). The control group did not receive anti-viral prophylaxis after ATG treatment, whereas valacyclovir maintenance (2 g four times a day by mouth) was performed until 1 month after completion of ATG treatment in the valacyclovir group. Plasma CMV DNA real-time polymerase chain reaction (RT-PCR) was checked on 7 days, 1, 3, 6, 9, and 12 months after ATG treatment.](kjim-2017-040f1){#f1-kjim-2017-040}

![Comparison of the incidence of cytomegalovirus (CMV) infection and CMV-free survival rate between the control (CONT) and valacyclovir (VAL) groups. (A) Incidence of CMV infection. (B) Kaplan-Meier curves for the CMV-free survival rate. Note that the VAL group showed significantly lower incidence of CMV infection and the CMV-free survival rate was also higher compared with that in the CONT group (*p* \< 0.01 for each). ^a^*p* \< 0.01 vs. CONT.](kjim-2017-040f2){#f2-kjim-2017-040}

![Comparison of the incidence of subsequent acute rejection, graft survival rate, and allograft function after anti-thymocyte globulin (ATG) treatment. (A) Subsequent acute rejection. (B) Kaplan-Meier curves for the graft survival rate. (C) Allograft function (CKD-EPI eGFR). Note that the incidence of subsequent acute rejection, graft survival, and allograft function after ATG treatment was not significantly different between the two groups (*p* \> 0.05 for each). CONT, control; VAL, valacyclovir; CMV, cytomegalovirus; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.](kjim-2017-040f3){#f3-kjim-2017-040}

###### 

Comparison of baseline characteristics

  Characteristic                          CONT (n = 34)   VAL (n = 21)   *p* value
  --------------------------------------- --------------- -------------- -----------
  Recipient age, yr                       41.7 ± 10       44.8 ± 12      0.298
  Recipient male, %                       50              33             0.272
  Immunologic status                                                     
   No. of HLA mismatch                    3.6 ± 2         3.2 ± 2        0.606
   Positive crossmatch                    0               2 (9.5)        0.141
   ABO incompatible                       3 (8.8)         4 (19.0)       0.408
   PRA \> 50%                             1 (2.9)         1 (4.8)        \> 0.999
  MDRD eGFR at biopsy, mL/min/1.73 m^2^   16.5 ± 10.9     23.3 ± 14.4    0.074
  Pathologic finding of rejection                                        0.304
   Acute TMR 1A                           8 (23.5)        5 (23.8)       
   Acute TMR 1B                           12 (35.3)       8 (38.3)       
   Acute TMR 2A                           11 (32.3)       3 (14.2)       
   Others                                 3 (8.8)         5 (23.8)       
  CMV seropositivity at baseline          28 (100)        17 (80.9)      0.391
  Time from transplantation to ATG, mon   20.2 ± 22       33.1 ± 35      0.101
  Duration of ATG administration, day     6.4 ± 2         5.9 ± 2        0.253
  Total dose of ATG, mg                   539 ± 216       472 ± 174      0.397
  Duration of VAL administration, day     \-              28.3 ± 5       

Values are presented as mean ± SD or number (%).

CONT, control; VAL, valacyclovir; HLA, human leukocyte antigen; PRA, panel reactive antibody; MDRD, modification of diet in renal disease; eGFR, estimated glomerular filtration rate; TMR, T-cell mediated rejection; CMV, cytomegalovirus; ATG, anti-thymocyte globulin antibody.

###### 

Comparison of adverse events

                     CONT (n = 34)   VAL (n = 21)   *p* value
  ------------------ --------------- -------------- -----------
  Anemia             11 (32)         5 (23)         0.556
  Leukopenia         8 (24)          7 (33)         0.272
  Thrombocytopenia   3 (9)           3 (14)         0.664

Values are presented as number (%).

CONT, control; VAL, valacyclovir.
